RxDoctor Payments Data

Andre Prochoroff, MD

Child & Adolescent Psychiatry · Cleveland, OHNPI 1376523670

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,350 of the $26,296 with a category attached, or 81.2%. Sarepta Therapeutics, Inc. accounts for 95.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $9,613 and has fallen 95.8% since, to $405 in 2025. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,296in general payments, 2019–2025

Across 42 payments — averaging $626.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$25K
  • NS Pharma, Inc.$413
  • Eli Lilly$350
  • Biogen$176
  • PTC Therapeutics, Inc.$78
  • Novartis$75
  • plus $93 from 2 others

What the payments were for

  • Consulting fees$21,35081%
  • Speaking & faculty fees$4882%
  • Travel & lodging$2,81111%
  • Food & beverage$1,4486%
  • Education$1991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$26,296 in reported general payments places this provider in the 95th percentile of 160 child & adolescent psychiatry providers in Ohio.

See all child & adolescent psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$1,249
Medicare patients
11
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amondys-45Casimersen70$2,043,122
EvrysdiRisdiplam29$772,394
SkyclarysOmaveloxolone11$352,615
Sodium Chloride0.9 % Sodium Chloride49$209
Prednisone16$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sarepta Therapeutics, Inc.Amondys-45$25,112$2,043,12270 claims
BiogenSkyclarys$176$352,61511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 child & adolescent psychiatry providers in Ohio.

Other child & adolescent psychiatry in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →